Alex and Dr. Scholz discuss the difference between Gleason 3+4=7 and 4+3=7.
0:48 What are the major differences between Gleason 3+4 and 4+3? In the Gleason system, the first number represents the most common grade on a biopsy slide and the second number represents the second most common grade. 4+3 and 3+4 are both intermediate-risk prostate cancers, but the treatment can vary greatly between the two Gleason grades and even within one of the Gleason grades. An unfavorable 4+3 will require combination therapy, a favorable 3+4 may be a candidate for active surveillance, and then everything in between.
3:41 What are the cure rates for men with 4+3? The cure rate for a favorable 4+3 is 90-95% and the cure rate for an unfavorable 4+3 is 75-80%.
Don’t know your stage? Take the quiz: Visit [ Ссылка ]
To learn more about prostate cancer visit [ Ссылка ]
To download the free Staging Guide visit [ Ссылка ]...
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate #MarkScholzMD
